Gilbert Dupont Healthcare Conference

Size: px
Start display at page:

Download "Gilbert Dupont Healthcare Conference"

Transcription

1 Gilbert Dupont Healthcare Conference Paris May 21, 2015

2 Disclaimer This presentation contains statements concerning Sartorius Stedim Biotech Group s future performance. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forwardlooking statements. Throughout this presentation, differences may be apparent as a result of rounding during addition.

3 Agenda Q Results Guidance 2015 Growth Prospects Company Overview Business Model Appendix

4 Continuing Strong Growth on All Lines Sartorius Stedim Biotech in million (unless otherwise specified) 3M M 2015 Change Change in cc 1) Sales Revenue in million Order intake % 17.1% Sales revenue % 21.5% Underlying EBITDA 2) % % cc Underlying EBITDA margin bps Underlying EPS 3) in % Q1 14 per qtr Q Order intake: fueled by strong demand for single use products and large equipment orders, delivery partly in 2016 Sales revenue: growth rate inflated by low comps; however, excellent performance ahead of expectations driven by all product lines Underlying EBITDA margin: up by 320 bps driven by economies of scale and fx-effects 1) cc= constant currencies 2) Underlying = excluding extraordinary items 3) Underlying EPS = based on net profit after noncontrolling interest, adjusted for extraordinary items, amortization and based on a normalized financial result and tax rate 4

5 Sales Growth Supported by All Regions Americas Sales 1) in million EMEA Sales 1) in million Asia Pacific Sales 1) in million Sales 1) by Regions in % EMEA ~ 48% mn Americas ~ 34% 3M14 3M15 3M14 3M15 3M14 3M % % % Definition of regions slightly changed; growth in constant currencies Asia Pacific ~ 18 % Dynamic business expansion in the Americas compared with a low base in Q Double-digit growth in EMEA due to strong demand for SU-products and equipment Continued sound development in Asia Pacific 1) According to customers location 5

6 P&L Impacted by Fx-Effects Sartorius Stedim Biotech Group in million 3M M 2015 Change Underlying EBITDA % Extraordinary items % Financial result n.m. Underlying net result 1) % Reported net result % Financial result burdened by derivatives fx-loans; mainly non-cash effective Net operating cash flow influenced by working capital build-up Net investing cash flow in line with expectations Net operating cash flow % Net investing cash flow 2) % 1) Underlying net result = net profit adjusted for extraordinary items, amortization and based on a normalized financial result and tax rate 2) Net cash flow from investing activities and acquisitions divestments 6

7 Financial Position Remained Strong Key Financial Indicators Net Debt to Underlying EBITDA Sartorius Stedim Biotech Group Dec March Equity ratio in % Net debt in million Net debt underlying EBITDA Q1-Q4 Q1-Q4 Q1-Q4 Q1-Q Q Net debt in mn (lhs) Net debt to underlying EBITDA (rhs) 7

8 Guidance 2015 Raised Previous 1) New 1) Sales revenue growth ~ 4% - 7% ~ 7% - 10% Underlying EBITDA margin ~ % ~ % Capex ratio ~ 6% - 8% 1) In constant currencies 8

9 Agenda Q Results Guidance 2015 Growth Prospects Company Overview Business Model Appendix

10 Strong Track Record of Profitable Growth Sales Revenue in million Earnings EBITDA 1) & margin CAGR ~ 12% CAGR ~ 17% ) Excluding extraordinary items 10

11 2020 Ambitious Long-Term Targets Supported by Growth Inititatives ~ 1.5 bn Sales Revenue ~ 28% ~2 3 Organic ~1 3 Acquisitions EBITDA margin 1) Strategic Initiatives Regional Growth Portfolio Extension Infrastructure Expansion 1) Excluding extraordinary items 11

12 Continuous Market Share Gains in the Americas Share of Sales 1) Sales Development Footprint Global biotech market ~ 50% CAGR 2) ~ 18% SSB ~ 32% New Oxford, USA Bohemia, USA Wilmington, USA Mexico City, Mexico Yauco, Puerto Rico Sales Production Biggest single market for biopharma Go-to-market initiative successfully executed; continuous market share gains Low double-digit organic growth rates targeted for the next years Figures in million; 1) FY 2014 Americas region 2) Constant currencies 12

13 Growth Initiative Asia: Leverage Strong Market Growth Share of Sales 1) Sales Development Footprint 100% 75% Other Japan CAGR 2) ~ 16% Beijing, China Shanghai, China Seoul, Korea Tokyo, Japan ~ 21% 50% 25% India South Korea 95.1 Bangalore, India Kuala Lumpur, Malaysia Singapore, Singapore China 0% Sales Production Dynamic market growth; Asia is the center for global biosimilars development New sales headquarters in Shanghai opened in 2013; new test & training lab in 2014 Continued double-digit organic growth projected for the next few years Melbourne, Australia Figures in million; 1) FY 2014 Asia Pacific region 2) Constant currencies 13

14 Emerging Biosimilars Market Offers Additional Growth Opportunities Strong biosimilars pipeline driven by patent expiries Biosimilars market forecast to expand fourfold, reaching $10bn by 2020 > 200 companies have > 700 biosimilars in global R&D pipelines Production capacities mainly built up in Asia First biosimilar approved in Europe in 2007; first approval by FDA in March 2015 Source: IMS MIDAS, 06/2013, IMS patent focus; Copaxone may see a conventional generic copy, not a biosimilar; Biosimilars Set to Revolutionize Global Drug Development Industry, Thomson Reuters, Sept

15 Portfolio Continuously Enhanced In-Line with Strategy ~ 588 mn ~ 477 mn Lonza Cell Culture Media TAP Biosystems AllPure Technologies BioOutsource 1) FY 2011 Sales Q Q Q FY 2014 Sales 1) Acquisition announced April 17,

16 Extension of SSB s Offering Through Acquisition of BioOutsource BioOutsource provides contract testing services to monitor the quality and safety of biologics Comprehensive suite of services, particularly for the biosimilars industry Headquartered in Glasgow; sales revenues of ~ 9 mn; ~ 85 employees Strong complementary fit with SSB s offering Validation Services Analytical Services Comparability testing Immunogenicity testing Lot release and stability testing Process Upscaling Biopharma customers Biosafety Services Cell bank characterization Bulk harvest characterization Lot release and stability testing Process Optimization Cell Culture Media 16

17 Acquisitions Remain Part of Our Strategy Acquisition Criteria Portfolio Complementary products or technologies Market Position Either among the Top 3 or unique position Integration Management capacity; cultural fit Price Fair valuation; reach Sartorius profitability level in 2-3 years Market environment: Increasingly consolidated due to numerous transactions Start-ups with innovative technologies 17

18 Continued Capacity Extension to Accommodate Growth Capex Ratio in % of sales revenue ~ e 1) Modernize and expand production capacity in UK for SSB s lab products Multi-year investment program to expand Goettingen site Further extension of membrane production capacity; additional R&D and application labs Capacity expansion at bag site in Tunisia Capex ratio projected at ~ 6% - 8% for 2015; expected to remain in this corridor for the next few years 1) Based on 2015 guidance 18

19 Agenda Q Results Guidance 2015 Growth Prospects Company Overview Business Model Appendix

20 Sartorius Stedim Biotech in Brief Sales revenue ~ 684 mn Sales Share 2) EBITDA 1) ~ 160 mn EBITDA 1) margin 23.5% Employees ~ 3,700 Americas ~ 32% EMEA ~ 47% Asia ~ 21% Market capitalization ~ 2.5 bn FY 2014 data 1) Underlying = excluding extraordinary items 2) Acc. to customers location; definition of regions slightly changed 20

21 Solution Provider for Biomanufacturing Supplier of key production technologies for the strongly growing biopharma industry Product quality & safety and supply security are decisive factors due to significant regulatory requirements (validated processes) Paradigm shift towards single-use solutions driven by multiple advantages SSB with broadest product portfolio in the industry, with a clear focus on single-use Single-use ~ 75 % Equipment ~ 25 % ~ 684 mn FY 2014 data 21

22 SSB Operates in a Healthy Market Environment CAGR 1) 6-8% Market Growth 16% % % Conventional Unclassified Biotechnology Overproportionate Growth of Biopharma Market Past Present Technology Trends From Multi-Use to Single-Use 1) Biotech market; Evaluate Pharma: World Preview ; June

23 The Widest Product Portfolio Across the Biopharma Process Chain Upstream Bioprocessing Downstream Bioprocessing Media Preparation Seed Fermentation Production Fermentation Cell Removal Clarification Capture Polishing Viral Clearance Formulation Final Fill Services Evaluation & Optimization Engineering & Design Implementation & Technical Services 23

24 Leading Positions in Key Technology Platforms Filtration Fluid Management Fermentation Purification Cell Culture Media SSB Merck Millipore Pall Thermo GE Top 3 Players 1. Pall 2. Merck Millipore 3. SSB 1. SSB 2. Thermo Fisher 3. Merck Millipore 1. SSB 2. Thermo Fisher 3. GE 1. GE 2. Merck Millipore 3. Pall 1. Thermo Fisher 2. Sigma 3. GE Pie charts indicate completeness of product offering Announced acquisitions of Sigma-Aldrich by Merck Millipore and Pall by Danaher not yet considered 24

25 100% Direct Business With Limited Dependence on Individual Accounts Sales to Top 50 customers in 2014, in million ~25% ~35% ~40% ~45% ~50% Cumulative Share Top to to to to 50 Long term business relationships with leading global (bio-)pharma companies Limited dependence on individual accounts Approx. half of 2014 revenue was generated with the Top 50 customers No individual customer accounts for more than 5% of sales revenue No single drug accounts for more than 2% of sales revenue 25

26 Agenda Q Results Guidance 2015 Growth Prospects Company Overview Business Model Appendix

27 Shareholding Structure ~ 26 % Sartorius 1) (~ 85 % of voting rights) Free float (~ 15 % of voting rights) ~ 74 % Total number of shares 2) Total number of voting rights 2) ~ 15.4 million ~ 27.0 million 1) Sartorius AG and VL Finance, which is 100% controlled by Sartorius AG 2) As of March

28 Strong Worldwide Presence Rotterdam Vilvoorde Epsom Royston Herlev Wilmington Bohemia New Oxford Glasgow Dublin Stonehouse Tagelswangen Lourdes Madrid Aubagne Goettingen Guxhagen Budapest Vienna Florence Mohamdia Poznan Beijing Seoul Tokyo Mexico City Yauco Hanoi Bangalore Kuala Lumpur Singapore São Paulo Buenos Aires Melbourne Sales Production Production and Sales 28

29 Further Driving Differentiation in Upstream Bioprocessing SU bioreactors up 2,000L SU media prep solutions up to > 2,000L Process engineering services Cell culture media SU & stainless steel options Scalable, automated SU multi-parallel bioreactors Sensors, chemometrics, data management SSB Announced acquisition of Sigma-Aldrich by Merck Millipore not yet considered 86 29

30 Main Credit Facility Refinanced in 2014 Attractive credit market conditions used 250 million syndicated loan terminated ahead of schedule New syndicated loan agreement entered into by Sartorius AG Since end of 2014 Sartorius Stedim Biotech uses a credit line of 300 million provided by Sartorius AG Annual cost savings of ~ 1 million 30

31 Sartorius Stedim Biotech Group Executive Committee Joachim Kreuzburg, CEO since 2007 Volker Niebel since 2007 Oscar-Werner Reif since 2009 Reinhard Vogt since 2007 Finance, Human Ressources, Compliance, Legal Affairs, Corporate Communications Production, Supply Chain Mgmt., Business Process Mgmt., Information Technology Research & Development Marketing, Sales & Services 31

32 Financial Calendar July 21, 2015 Publication of half-year 2015 figures October 20, 2015 Publication of nine-month 2015 figures January 2016 Publication of preliminary full-year 2016 figures April 5, 2016 Annual General Shareholders Meeting, Aubagne 32

33 Contacts Petra Kirchhoff Vice President Corporate Communications & IR Phone: Andreas Theisen Director Investor Relations Phone: Sartorius Corporate Administration GmbH Weender Landstrasse Goettingen, Germany 33

HSBC s 13th Equity Conference. Paris March 31, 2015

HSBC s 13th Equity Conference. Paris March 31, 2015 HSBC s 13th Equity Conference Paris March 31, 2015 Disclaimer This presentation contains statements concerning the Sartorius Group s future performance. These statements are based on assumptions and estimates.

More information

Conference Call 9M 2015 Results

Conference Call 9M 2015 Results Conference Call 9M 2015 Results Joachim Kreuzburg, CEO October 20, 2015 Disclaimer This presentation contains statements concerning the future performance of the Sartorius Group and the Sartorius Stedim

More information

Conference Call Preliminary Full-Year Results 2014

Conference Call Preliminary Full-Year Results 2014 Conference Call Preliminary Full-Year Results 2014 Joachim Kreuzburg, CEO January 27, 2015 Disclaimer This presentation contains statements concerning the future performance of the Sartorius Group and

More information

Unfolding your potential. Discovering opportunities for your future. Transforming knowledge into results. Sartorius Scholarship

Unfolding your potential. Discovering opportunities for your future. Transforming knowledge into results. Sartorius Scholarship Unfolding your potential Discovering opportunities for your future Transforming knowledge into results Sartorius Scholarship From campus to company Are you an excellent student? Do you already have your

More information

Life Science - a sustainable platform for profitable growth

Life Science - a sustainable platform for profitable growth Life Science - a sustainable platform for profitable growth 2012 Life Science Information Day Bernd Reckmann Member of the Executive Board and Head of Chemicals Molsheim, France - December 5, 2012 Agenda

More information

CONFERENCE CALL PRELIMINARY FIGURES FISCAL YEAR 2014

CONFERENCE CALL PRELIMINARY FIGURES FISCAL YEAR 2014 WELCOME DÜRR AKTIENGESELLSCHAFT CONFERENCE CALL PRELIMINARY FIGURES FISCAL YEAR 2014 Ralf W. Dieter, CEO Ralph Heuwing, CFO Bietigheim-Bissingen, March 9, 2015 www.durr.com DISCLAIMER This presentation

More information

Health Care Worldwide. Citi - European Credit Conference September 24, 2015 - London

Health Care Worldwide. Citi - European Credit Conference September 24, 2015 - London Health Care Worldwide Citi - European Credit Conference September 24, 2015 - London Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties.

More information

Fourth Quarter 2015 Conference Call

Fourth Quarter 2015 Conference Call Fourth Quarter 2015 Conference Call E. Scott Santi, Chairman & CEO Michael M. Larsen, Senior Vice President & CFO Aaron H. Hoffman, Vice President, Investor Relations January 27, 2016 Forward Looking Statements

More information

Focus on fleet customers SAF-HOLLAND Annual Financial Statements 2013

Focus on fleet customers SAF-HOLLAND Annual Financial Statements 2013 Focus on fleet customers SAF-HOLLAND Annual Financial Statements 213 Detlef Borghardt, CEO Wilfried Trepels, CFO March 13, 214 Agenda 1 Financials 3 2 Appendix 21 2 Executive Summary 1 2 3 Group sales

More information

Credit Suisse Global Health Care Conference. March 5, 2013

Credit Suisse Global Health Care Conference. March 5, 2013 Credit Suisse Global Health Care Conference March 5, 2013 Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results

More information

A Leading Global Health Care Group

A Leading Global Health Care Group A Leading Global Health Care Group Commerzbank German Investment Seminar January 11/12, 2016 For detailed financial information please see our annual/quarterly reports and/or conference call materials

More information

CONFERENCE CALL PRELIMINARY FIGURES FISCAL YEAR 2013

CONFERENCE CALL PRELIMINARY FIGURES FISCAL YEAR 2013 WELCOME DÜRR AKTIENGESELLSCHAFT CONFERENCE CALL PRELIMINARY FIGURES FISCAL YEAR 2013 Ralf W. Dieter, CEO Ralph Heuwing, CFO Bietigheim-Bissingen, February 25, 2014 www.durr.com DISCLAIMER This presentation

More information

Health Care Worldwide

Health Care Worldwide Health Care Worldwide Goldman Sachs - Leveraged Finance Healthcare Conference March 4, 2014 New York Goldman Sachs Leveraged Finance Conference, Fresenius SE & Co. KGaA Copyright, March 4, 2014 Page 1

More information

A Leading Global Health Care Group

A Leading Global Health Care Group A Leading Global Health Care Group JP Morgan Milan Investor Forum October 1, 2015 For detailed financial information please see our annual/quarterly reports and/or conference call materials on www.fresenius.com/ir.

More information

Third quarter results FY2015. August 17, 2015

Third quarter results FY2015. August 17, 2015 Third quarter results FY2015 August 17, 2015 Disclaimer Stabilus S.A. (the Company, later Stabilus ) has prepared this presentation solely for your information. It should not be treated as giving investment

More information

Dresdner Kleinwort German Investment Seminar. January 14-16, 2008

Dresdner Kleinwort German Investment Seminar. January 14-16, 2008 Dresdner Kleinwort German Investment Seminar January 14-16, 2008 Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future

More information

Investor & Analyst Presentation Acquisition of Centor US Holding Inc. Uwe Röhrhoff, CEO Rainer Beaujean, CFO Duesseldorf, July 28, 2015

Investor & Analyst Presentation Acquisition of Centor US Holding Inc. Uwe Röhrhoff, CEO Rainer Beaujean, CFO Duesseldorf, July 28, 2015 Investor & Analyst Presentation Acquisition of Centor US Holding Inc. Uwe Röhrhoff, CEO Rainer Beaujean, CFO Duesseldorf, July 28, 2015 Disclaimer 1. This presentation may contain certain forward-looking

More information

Health Care Worldwide

Health Care Worldwide Health Care Worldwide Barclays European High Yield and Leveraged Finance Conference October 30, 2014 London Barclays European High Yield and Leveraged Finance Conference, October 30, 2014 Copyright Page

More information

UDG Healthcare plc An International Healthcare Services Organisation

UDG Healthcare plc An International Healthcare Services Organisation UDG Healthcare plc An International Healthcare Services Organisation Jefferies 2014 Global Healthcare Conference 2014 Liam FitzGerald, CEO 20 November 2014 1 FORWARD LOOKING STATEMENTS Some statements

More information

ITW Conference Call Third Quarter 2013

ITW Conference Call Third Quarter 2013 ITW Conference Call Third Quarter 2013 October 22, 2013 SOLID GROWTH. STRONG RETURNS. BEST-IN-CLASS OPERATOR. Forward-Looking Statements Safe Harbor Statement This conference call contains forward-looking

More information

Full Year Results 2014

Full Year Results 2014 Full Year Results 2014 18 March 2015 Conference call on FY Results 2014 Corporate Finance & Investor Relations AGENDA FY 2014 results presentation Highlights 2014 Financials 2014 Outlook 2015 Appendix

More information

A Leading Global Health Care Group

A Leading Global Health Care Group A Leading Global Health Care Group Credit Suisse Global Health Care Conference, March 4, 2015 For detailed financial information please see our annual/quarterly reports and/or conference call materials

More information

Midyear Presentation 2013. market strategy

Midyear Presentation 2013. market strategy Midyear Higher order Results intake, Presentation lower profitability 2013 focused market strategy THE SAFE HARBOR STATEMENT UNDER THE US PRIVATE SECURITIES LITIGATION REFORM ACT 1995 This presentation

More information

Lonza Reports Record First Quarter

Lonza Reports Record First Quarter Pharma&Biotech Lonza Reports Record First Quarter Q1 2016 Qualitative Business Update 26 April 2016 Richard Ridinger CEO Lonza Additional Information and Disclaimer Lonza Group Ltd has its headquarters

More information

Company Presentation VTG AG Connecting worlds. Analyst Conference April 14, 2015

Company Presentation VTG AG Connecting worlds. Analyst Conference April 14, 2015 Company Presentation VTG AG Connecting worlds Analyst Conference April 14, 2015 Table of content 1 Highlights 2014 2 Performance & Financials 2014 3 Update on Strategy 4 Outlook 2015 5 Appendix 1 Executive

More information

Health Care Worldwide

Health Care Worldwide Health Care Worldwide Credit Suisse Global Credit Products Conference September 18, 2014 Miami Credit Suisse Global Credit Products Conference, September 18, 2014 Copyright Page 1 Safe Harbor Statement

More information

2013 Half Year Results

2013 Half Year Results 2013 Half Year Results Erwin Stoller, Executive Chairman Joris Gröflin, Chief Financial Officer Agenda 1. Introduction and summary of first half year 2013 2. Financial results first half year 2013 3. Outlook

More information

IFGL REFRACTORIES LTD. RESULT UPDATE PRESENTATION, February 2016

IFGL REFRACTORIES LTD. RESULT UPDATE PRESENTATION, February 2016 IFGL REFRACTORIES LTD RESULT UPDATE PRESENTATION, February 2016 Safe Harbor This presentation and the accompanying slides (the Presentation ), has been prepared by IFGL Refractories Limited (the Company

More information

Ludwigshafen, February 25, 2014

Ludwigshafen, February 25, 2014 Ludwigshafen, February 25, 2014 Analyst Conference FY2013 Cautionary note regarding forward-looking statements This presentation may contain forward-looking statements that are subject to risks and uncertainties,

More information

Delivering sustainable global growth

Delivering sustainable global growth Delivering sustainable global growth Driving profits by growing third party assets Keith Skeoch CEO, Standard Life Investments This presentation may contain certain forward-looking statements with respect

More information

Announcement of Completion of Heraeus Holding GmbH s Dental Materials Business Share Purchase

Announcement of Completion of Heraeus Holding GmbH s Dental Materials Business Share Purchase July 1, 2013 Mitsui Chemicals, Inc. Announcement of Completion of Heraeus Holding GmbH s Dental Materials Business Share Purchase Mitsui Chemicals, Inc. (Toshikazu Tanaka, President & CEO) announced in

More information

A Leading Global Health Care Group

A Leading Global Health Care Group A Leading Global Health Care Group HSBC Healthcare Day, November 12, 2014 For detailed financial information please see our annual/quarterly reports and/or conference call materials on www.fresenius.com/ir.

More information

THOMSON REUTERS SECOND QUARTER 2009. August 6, 2009

THOMSON REUTERS SECOND QUARTER 2009. August 6, 2009 THOMSON REUTERS SECOND QUARTER 2009 August 6, 2009 Agenda Welcome / Introduction Frank Golden Second Quarter Results & Highlights Tom Glocer Market Environment Update Unification Proposal Update Financial

More information

Full Year Results 2012. Conference Call Presentation, 21 st March 2013

Full Year Results 2012. Conference Call Presentation, 21 st March 2013 Full Year Results 2012 Conference Call Presentation, 21 st March 2013 0 Disclaimer This presentation may contain forward-looking statements based on current assumptionsandforecastsmadebybrenntag AG and

More information

Drägerwerk AG & Co. KGaA Analyst Conference 2015. Frankfurt, March 11, 2015

Drägerwerk AG & Co. KGaA Analyst Conference 2015. Frankfurt, March 11, 2015 Drägerwerk AG & Co. KGaA Analyst Conference 2015 Frankfurt, March 11, 2015 Disclaimer This presentation does not constitute an offer of securities for sale or a solicitation of an offer to purchase any

More information

KONE s interim report for January March 2016 APRIL 21, 2016 HENRIK EHRNROOTH, PRESIDENT & CEO

KONE s interim report for January March 2016 APRIL 21, 2016 HENRIK EHRNROOTH, PRESIDENT & CEO KONE s interim report for January March 2016 APRIL 21, 2016 HENRIK EHRNROOTH, PRESIDENT & CEO Figures for January March 2016 Q1 2016 Key figures STRONG OPERATING PERFORMANCE; ORDERS DECLINED FROM A HIGH

More information

SAF-HOLLAND Annual Financial Statements 2012. Detlef Borghardt, CEO Wilfried Trepels, CFO. March 14, 2013

SAF-HOLLAND Annual Financial Statements 2012. Detlef Borghardt, CEO Wilfried Trepels, CFO. March 14, 2013 SAF-HOLLAND Annual Financial Statements 212 Detlef Borghardt, CEO Wilfried Trepels, CFO March 14, 213 Executive Summary business volume successfully expanded in 212 1 Group sales increased yoy by 3.4%

More information

A LEADING GLOBAL HEALTHCARE COMPANY

A LEADING GLOBAL HEALTHCARE COMPANY A LEADING GLOBAL HEALTHCARE COMPANY Roadshow Boston March 2, 2016 Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY www.fresenius.com/investors SAFE HARBOR STATEMENT This presentation contains

More information

Bioprocessing Media and Buffers Grow with Us

Bioprocessing Media and Buffers Grow with Us Bioprocessing Media and Buffers Grow with Us Experience Highly experienced media on the selection of standard media as well as development This service packaging, documentation Leading position in single-use

More information

Cliquez pour modifier le style des sous-titres du masque

Cliquez pour modifier le style des sous-titres du masque 2012 Results Growth in Revenue and Profit Investments in the most dynamic markets Cliquez pour modifier le style des sous-titres du masque Venice, 2012 Results 2012 Performance delivered Solid balance

More information

Q1/2015 Results VTG AG Connecting worlds. Dr. Heiko Fischer, CEO Dr. Kai Kleeberg, CFO May 21, 2015

Q1/2015 Results VTG AG Connecting worlds. Dr. Heiko Fischer, CEO Dr. Kai Kleeberg, CFO May 21, 2015 Q1/2015 Results VTG AG Connecting worlds Dr. Heiko Fischer, CEO Dr. Kai Kleeberg, CFO May 21, 2015 Table of content 1 Discussion of Q1/2015 2 Outlook FY 2015 3 Questions & Answers 4 Financial Calendar

More information

Financial Information

Financial Information Financial Information Solid results with in all key financial metrics of 23.6 bn, up 0.4% like-for like Adjusted EBITA margin up 0.3 pt on organic basis Net profit up +4% to 1.9 bn Record Free Cash Flow

More information

Q1 2014 Earnings Call. April 30 th, 2014

Q1 2014 Earnings Call. April 30 th, 2014 Q1 2014 Earnings Call April 30 th, 2014 Agenda Executive summary Financial data Outlook 2014 Appendix 2 Summary Q1 2014 (1) Revenue growth factors Positive start in FY 2014 with Q1 revenue increase of

More information

Full-year results 2014. December 02, 2014

Full-year results 2014. December 02, 2014 Full-year results 2014 December 02, 2014 Disclaimer Stabilus S.A. (the Company, later Stabilus ) has prepared this presentation solely for your information. It should not be treated as giving investment

More information

Health Care Worldwide. Deutsche Bank European Leveraged Finance Conference June 14, 2013 London

Health Care Worldwide. Deutsche Bank European Leveraged Finance Conference June 14, 2013 London Health Care Worldwide Deutsche Bank European Leveraged Finance Conference June 14, 2013 London Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks

More information

H1/2014 Results VTG AG Growing together. Dr. Heiko Fischer, CEO Dr. Kai Kleeberg, CFO August 21, 2014

H1/2014 Results VTG AG Growing together. Dr. Heiko Fischer, CEO Dr. Kai Kleeberg, CFO August 21, 2014 H1/2014 Results VTG AG Growing together Dr. Heiko Fischer, CEO Dr. Kai Kleeberg, CFO August 21, 2014 Table of content 1 Discussion of H1/2014 2 Outlook FY 2014 3 Questions & Answers 4 Financial Calendar

More information

Preliminary results FY2015. November 27, 2015

Preliminary results FY2015. November 27, 2015 Preliminary results FY2015 November 27, 2015 Disclaimer Stabilus S.A. (the Company, later Stabilus ) has prepared this presentation solely for your information. It should not be treated as giving investment

More information

Second Quarter 2015 Investor Conference Call

Second Quarter 2015 Investor Conference Call Second Quarter 2015 Investor Conference Call August 20, 2015 December 13, 2012 DRAFT 5 Safe Harbor Basis of Presentation Unless otherwise noted or unless the context otherwise requires, all references

More information

CONFERENCE CALL RESULTS JANUARY MARCH 2014

CONFERENCE CALL RESULTS JANUARY MARCH 2014 WELCOME DÜRR AKTIENGESELLSCHAFT CONFERENCE CALL RESULTS JANUARY MARCH 2014 Ralf W. Dieter, CEO Ralph Heuwing, CFO Bietigheim-Bissingen, May 6, 2014 www.durr.com DISCLAIMER This presentation has been prepared

More information

IMCD reports strong results for 2014

IMCD reports strong results for 2014 IMCD reports strong results for 2014 Rotterdam, The Netherlands 11 March 2015 - IMCD N.V. ( IMCD or Company ), a leading international speciality chemicals-focused distributor, today announces the 2014

More information

Acquisition of SAIT Communications. 28 July 2015

Acquisition of SAIT Communications. 28 July 2015 Acquisition of SAIT Communications 28 July 2015 Conference call details SpeedCast acquires SAIT Communications The company has scheduled a conference call as follows: Time: 11.00am (Sydney time), 28 th

More information

Dr. Reddy s Q3 and 9M FY16 Financial Results

Dr. Reddy s Q3 and 9M FY16 Financial Results Press Release DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS KEDAR UPADHYE kedaru@drreddys.com (Ph: +91-40-66834297) CONTACT

More information

Focus on fleet customers SAF-HOLLAND 1st half-year results 2014

Focus on fleet customers SAF-HOLLAND 1st half-year results 2014 Focus on fleet customers SAF-HOLLAND 1st half-year results 214 Detlef Borghardt, CEO Wilfried Trepels, CFO August 7, 214 Executive Summary 1 Increase in group sales by 1.7% to 482.mn (previous year: 435.6)

More information

ACETO Corporation Investor Presentation November 2, 2016

ACETO Corporation Investor Presentation November 2, 2016 NASDAQ:ACET ACETO Corporation Investor Presentation November 2, 2016 Sourcing & Supplying Quality Products Worldwide Disclosure This presentation contains forward-looking statements, as defined by the

More information

Group Quarterly Statement January March 2016

Group Quarterly Statement January March 2016 Sharing values Growing Together Group Quarterly Statement January March 2016 Group sales increase 10 % to 732 million Sales increase 14 % compared to the previous year at local currency Solid growth in

More information

Q1 Trading Update, FY 2011

Q1 Trading Update, FY 2011 ARYZTA AG Q1 Trading Update, FY 2011 29 November 2010 Forward Looking Statement This document contains forward looking statements which reflect management s current views and estimates. The forward looking

More information

Paris Orléans. Full year 2013/2014 results presentation

Paris Orléans. Full year 2013/2014 results presentation Paris Orléans Full year 2013/2014 results presentation 25 June 2014 Contents Sections 1 Highlights of 2013/2014 2 2 Business review 4 3 Financial review 9 Appendices 23 1 1. Highlights of 2013/2014 1.

More information

CONFERENCE CALL RESULTS JANUARY SEPTEMBER 2015

CONFERENCE CALL RESULTS JANUARY SEPTEMBER 2015 WELCOME DÜRR AKTIENGESELLSCHAFT CONFERENCE CALL RESULTS JANUARY SEPTEMBER 2015 Ralf W. Dieter, CEO Ralph Heuwing, CFO Bietigheim-Bissingen, November 3, 2015 www.durr.com DISCLAIMER This presentation has

More information

GE 2014 third quarter performance

GE 2014 third quarter performance GE 2014 third quarter performance Financial results & Company highlights October 17, 2014 Forward-Looking Statements: This document contains forward-looking statements that is, statements related to future,

More information

Financial Results. siemens.com

Financial Results. siemens.com s Financial Results Fourth Quarter and Fiscal 2015 siemens.com Key figures (in millions of, except where otherwise stated) Volume Q4 % Change Fiscal Year % Change FY 2015 FY 2014 Actual Comp. 1 2015 2014

More information

2015 Second Quarter Business Review (unaudited) July 23, 2015

2015 Second Quarter Business Review (unaudited) July 23, 2015 2015 Second Quarter Business Review (unaudited) July 23, 2015 1 Forward Looking Statement This presentation contains forward-looking information about 3M's financial results and estimates and business

More information

Acquisition of GEKA GmbH

Acquisition of GEKA GmbH Acquisition of GEKA GmbH Creating a leader in high precision plastic injection molding technologies for innovative B2B mixing and applicator solutions July 4, 2016 Acquisition of GEKA GmbH THE SAFE HARBOR

More information

A Leading Global Health Care Group

A Leading Global Health Care Group A Leading Global Health Care Group Commerzbank Sector Conference September 8, 2014 For detailed financial information please see our annual/quarterly reports and/or conference call materials on www.fresenius.com/ir.

More information

Nemetschek Group Company Presentation. July 2014

Nemetschek Group Company Presentation. July 2014 Nemetschek Group Company Presentation July 2014 Agenda Nemetschek Group: In brief Strategy Internationalization Industry mega trends Innovations Financial data Q1 2014 Nemetschek share Why invest? 2 A

More information

Supplemental Information Fourth Quarter 2010 Earnings Call

Supplemental Information Fourth Quarter 2010 Earnings Call Supplemental Information Fourth Quarter 2010 Earnings Call Market & Financial Overview Capital Values Q4 2009 Q4 2010 London Shanghai Beijing, Hong Kong Moscow Washington DC New York, Paris, San Francisco

More information

dbaccess European TMT Conference

dbaccess European TMT Conference dbaccess European TMT Conference London, UK September 03 & 04, 2013 Safe-Harbor-Statement This presentation contains forward-looking statements based on beliefs of Software AG management. Such statements

More information

ABENGOA. 2014: Financial Review. Barbara Zubiria. 8th Annual Analyst and Investor Day. EVP, Capital Markets & IR

ABENGOA. 2014: Financial Review. Barbara Zubiria. 8th Annual Analyst and Investor Day. EVP, Capital Markets & IR Innovative Technology Solutions for Sustainability ABENGOA 2014: Financial Review Barbara Zubiria EVP, Capital Markets & IR 8th Annual Analyst and Investor Day April 3 & 4, 2014 Forward-looking Statement

More information

1) Substantially all of these team members are employed by our franchisees. 2) 99% of system-wide sales are franchise sales, which represent sales at

1) Substantially all of these team members are employed by our franchisees. 2) 99% of system-wide sales are franchise sales, which represent sales at This presentation contains certain forward-looking statements, which reflect management's expectations regarding future events and operating performance and speak only as of the date hereof. These forward-looking

More information

SpeeCo Acquisition Overview. August 10, 2010

SpeeCo Acquisition Overview. August 10, 2010 SpeeCo Acquisition Overview August 10, 2010 Safe Harbor Statements in this document that are not based upon historic, reported financial results or other historical information are forward-looking statements

More information

Software AG Results 1 st Quarter 2015 (IFRS, unaudited)

Software AG Results 1 st Quarter 2015 (IFRS, unaudited) Software AG Results 1 st Quarter (IFRS, unaudited) April 29, 1 Safe Harbor This presentation includes forward-looking statements based on the beliefs of Software AG management. Such statements reflect

More information

Healthcare Solid performance, strong perspectives Siemens Capital Market Day Berlin, December 9, 2014

Healthcare Solid performance, strong perspectives Siemens Capital Market Day Berlin, December 9, 2014 Hermann Requardt Member of the Managing Board & Healthcare CEO Healthcare Solid performance, strong perspectives Siemens Capital Market Day Notes and forward-looking statements This document contains statements

More information

Financial Repression: A Driving Force for Mergers and Acquisitions?

Financial Repression: A Driving Force for Mergers and Acquisitions? Strategy / Investment Financial Repression: A Driving Force for Mergers and Acquisitions? International capital markets have seen a growing number of corporate mergers and acquisitions (M&A) over the past

More information

Colliers International Group Inc. Investor Presentation

Colliers International Group Inc. Investor Presentation Colliers International Group Inc. Investor Presentation Basis of Presentation All amounts in millions of US Dollars unless otherwise noted. Adjusted EBITDA ( AEBITDA ) and Adjusted EPS ( AEPS ) are non-gaap

More information

Results Announcement for the half year ending 31 December 2013. Centuria Capital Limited Presentation to Investors and Analysts

Results Announcement for the half year ending 31 December 2013. Centuria Capital Limited Presentation to Investors and Analysts Results Announcement for the half year ending 31 December 2013 Centuria Capital Limited Presentation to Investors and Analysts Half year summary First half year performance in line with expectations Underlying

More information

1) Substantially all of these team members are employed by our franchisees. 2) ~100% of system-wide sales are franchise sales, which represent sales

1) Substantially all of these team members are employed by our franchisees. 2) ~100% of system-wide sales are franchise sales, which represent sales This presentation contains certain forward-looking statements, which reflect management's expectations regarding future events and operating performance and speak only as of the date hereof. These forward-looking

More information

Full Year 2015 Results

Full Year 2015 Results Full Year 2015 Results 16 March 2016 Conference call on FY 2015 results Corporate Finance & Investor Relations AGENDA FY 2015 results presentation Highlights 2015 Financials 2015 Outlook 2016 Appendix

More information

Nordex SE Conference Call 9M 2012. Hamburg, 13/11/2012

Nordex SE Conference Call 9M 2012. Hamburg, 13/11/2012 Nordex SE Conference Call 9M 2012 Hamburg, 13/11/2012 AGENDA 1. Highlights 9M 2012 Dr. J. Zeschky 2. Financials 9M 2012 B. Schäferbarthold 3. Guidance 2012 and market outlook B. Schäferbarthold 4. Strategy

More information

Strong Q2 Outlook increased

Strong Q2 Outlook increased www.osram.com Strong Q2 Outlook increased Q2 FY15 Management Presentation (preliminary figures) April 29, 2015 Light is OSRAM Safe Harbor Statement This presentation may contain forward-looking statements

More information

Commerzbank German Investment Seminar. January 14 15, 2013

Commerzbank German Investment Seminar. January 14 15, 2013 Commerzbank German Investment Seminar January 14 15, 2013 Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results

More information

Q1 2016 Results Conference Call

Q1 2016 Results Conference Call Q1 2016 Results Conference Call Karim Bohn, CFO 10 May 2016 PATRIZIA Immobilien AG PATRIZIA Bürohaus Fuggerstrasse 26 86150 Augsburg T +49 821 50910-000 F +49 821 50910-999 immobilien@patrizia.ag www.patrizia.ag

More information

JENOPTIK AG Conference Call Results of fiscal year 2015 and outlook

JENOPTIK AG Conference Call Results of fiscal year 2015 and outlook JENOPTIK AG Conference Call Results of fiscal year 215 and outlook March 22, 216 Dr. Michael Mertin, CEO Hans-Dieter Schumacher, CFO Copyright Jenoptik, All rights reserved. Ergebnisse des Geschäftsjahrs

More information

21 AUGUST 2015 ANALYST PRESENTATION. HY1 2015 results

21 AUGUST 2015 ANALYST PRESENTATION. HY1 2015 results 21 AUGUST ANALYST PRESENTATION results Forward-looking statements This presentation contains forward-looking statements, based on currently available plans and forecasts. By their nature, forward-looking

More information

Investor Presentation Q3 2014

Investor Presentation Q3 2014 Investor Presentation Q3 2014 Disclaimers Related to forward-looking statements This presentation may contain forward-looking statements that involve risks, uncertainties and other factors concerning,

More information

Debt Investors Call First Quarter 2015. Walldorf, Germany Monday, May 4, 2015

Debt Investors Call First Quarter 2015. Walldorf, Germany Monday, May 4, 2015 Debt Investors Call First Quarter 2015 Walldorf, Germany Monday, May 4, 2015 Safe Harbor Statement Any statements contained in this document that are not historical facts are forward-looking statements

More information

Investor Conference Call Acquisition of DRONCO GmbH

Investor Conference Call Acquisition of DRONCO GmbH Investor Conference Call Acquisition of DRONCO GmbH June 1, 2015 David Westgate CEO Sarah Sutton CFO Dial-in: 877-407-3982 http://investors.jasoninc.com Forward Looking Statements: Safe Harbor, Forward

More information

Results Presentation for Year Ended 30 June 2015 25 August 2015

Results Presentation for Year Ended 30 June 2015 25 August 2015 Results Presentation for Year Ended 30 June 2015 25 August 2015 Rene Sugo CEO Agenda Corporate Profile Financial Summary Business Overview TNZI Acquisition Update FY16 Roadmap 2 Corporate Profile 3 Corporate

More information

Analyst Conference Call Q1-3/12 Results. October 31, 2012

Analyst Conference Call Q1-3/12 Results. October 31, 2012 Analyst Conference Call Q1-3/12 Results October 31, 2012 Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results

More information

Sapiens results in the first quarter represent a solid start to achieving our financial targets for the full year.

Sapiens results in the first quarter represent a solid start to achieving our financial targets for the full year. Sapiens Reports 12% Year-Over-Year Increase in Quarterly Revenue to $41 Million Non-GAAP Quarterly Operating Profit Increased by 58.5% Year-Over-Year Holon, Israel, May 6, 2015 Sapiens International Corporation,

More information

For personal use only

For personal use only Integrated Research Limited (IRI) FY2015 Annual General Meeting 13 November, 2015 ABN: 76 003 588 449 9 of the top 10 US banks 4 of the world s 10 largest companies 6 of the 10 biggest stock exchanges

More information

Deutsche Bank 17th Annual European Leveraged Finance Conference. June 14, 2013 London

Deutsche Bank 17th Annual European Leveraged Finance Conference. June 14, 2013 London Deutsche Bank 17th Annual European Leveraged Finance Conference June 14, 2013 London Safe Harbor Statement: This presentation includes certain forward-looking statements within the meaning of Section 27A

More information

Earnings Release Q4 FY 2015 July 1 to September 30, 2015

Earnings Release Q4 FY 2015 July 1 to September 30, 2015 Munich, Germany, November 12, 2015 Earnings Release FY 2015 July 1 to September 30, 2015 Strong finish for fiscal 2015»We delivered what we promised, and are well positioned to deliver on our plans for

More information

Fresenius Kabi Creating a Global Leader in I.V. Generic Drugs. Conference Call, July 7, 2008

Fresenius Kabi Creating a Global Leader in I.V. Generic Drugs. Conference Call, July 7, 2008 Fresenius Kabi Creating a Global Leader in I.V. Generic Drugs Conference Call, July 7, 2008 Disclaimer THIS PRESENTATION IS FOR INFORMATION PURPOSES ONLY AND MAY NOT BE FURTHER DISTRIBUTED OR PASSED ON

More information

Production in an Innovation Economy: The Globalization of Biomanufacturing and Implications for the Geography of Innovation

Production in an Innovation Economy: The Globalization of Biomanufacturing and Implications for the Geography of Innovation Production in an Innovation Economy: The Globalization of Biomanufacturing and Implications for the Geography of Innovation Industry Studies Association Pittsburgh, June 1, 2011 Elisabeth Reynolds, Ph.D.

More information

Speech of the Board of Management. General Shareholders Meeting, 9 June 2015

Speech of the Board of Management. General Shareholders Meeting, 9 June 2015 Speech of the Board of Management General Shareholders Meeting, 9 June 2015 AGENDA Overview of the financial year Steven Holland, CEO Financial figures 2014 Georg Müller, CFO ConnectingChemistry Steven

More information

H1 2009 Earnings Release

H1 2009 Earnings Release H1 2009 Earnings Release Olivier Piou, CEO Jacques Tierny, CFO August 25, 2009 www.gemalto.com Disclaimer Forward-Looking Statements This communication contains certain statements that are neither reported

More information

CONFERENCE CALL Q1/2016 RESULTS. Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY www.fresenius.com/investors

CONFERENCE CALL Q1/2016 RESULTS. Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY www.fresenius.com/investors CONFERENCE CALL Q1/2016 RESULTS Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY www.fresenius.com/investors SAFE HARBOR STATEMENT This presentation contains forward-looking statements

More information

Burger King Worldwide, Inc. First Quarter 2013 Earnings Conference Call. April 26, 2013

Burger King Worldwide, Inc. First Quarter 2013 Earnings Conference Call. April 26, 2013 Burger King Worldwide, Inc. First Quarter 2013 Earnings Conference Call April 26, 2013 0 Safe Harbor Statement Certain statements made in this presentation that reflect management s expectations regarding

More information

A LEADING GLOBAL HEALTHCARE COMPANY

A LEADING GLOBAL HEALTHCARE COMPANY A LEADING GLOBAL HEALTHCARE COMPANY J.P. Morgan European Healthcare Conference June 23, 2016 Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY www.fresenius.com/investors SAFE HARBOR STATEMENT

More information

3 rd Quarter 2014 Earnings Conference Call Transcript

3 rd Quarter 2014 Earnings Conference Call Transcript 3 rd Quarter 2014 Earnings Conference Call Transcript Overview*: BDC reported 3Q14 consolidated revenues of $613.1M, income from continuing operations of $50.4M and diluted EPS from continuing operations

More information

2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q

2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q 2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q Copyright 2013 Quintiles Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements

More information